Welcome to Cyxone!

Cyxone develops new drugs based upon a natural plant protein

Cyxone AB is a biopharmaceutical company developing drugs based on cyclotides, a natural class of plant proteins, for immune-related diseases. Cyxone’s focus is to bring its drug candidate against MS, T20K, through preclinical studies and phase I clinical trials.

Upcoming events

Genesis Drug Discovery

Start date: May 10 2018

End date: May 11 2018

The CEO of Cyxone, Dr Kjell G Stenberg, will give a presentation at the Genesis Drug Discovery (GDD) Conference in Barcelona, Spain